Valuation: Precigen, Inc.

Market Cap 1.76B 1.54B 1.42B 1.31B 2.47B 170B 2.53B 17.01B 6.69B 83.23B 6.63B 6.48B 287B P/E 2026 *
-165x
P/E 2027 * 24.8x
Enterprise Value 1.76B 1.54B 1.42B 1.31B 2.47B 170B 2.53B 17.01B 6.69B 83.23B 6.63B 6.48B 287B EV / Sales 2026 *
14.2x
EV / Sales 2027 * 7.71x
Free-Float
86.29%
Yield 2026 *
-
Yield 2027 * -
1 week-6.95%
Current month-13.16%
1 month+2.70%
3 months+24.37%
6 months+12.24%
Current year+18.42%
1 week 4.81
Extreme 4.81
5.26
1 month 4.81
Extreme 4.81
6.04
Current year 3.04
Extreme 3.04
6.04
1 year 1.47
Extreme 1.47
6.04
3 years 0.65
Extreme 0.6513
6.04
5 years 0.65
Extreme 0.6513
6.46
10 years 0.65
Extreme 0.6513
32.9
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/10/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 01/02/2008
Director/Board Member 78 01/02/2008
Director/Board Member 70 28/11/2011
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Sell

Chief Financial Officer

-171,429 0.0574%
29/06/26 Fiscal year

Chief Operating Officer

128,772 0.0431%
29/06/26 Fiscal year

Chief Executive Officer

1,040,508 0.3486%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.95%+181.25%+263.97% 1.76B
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.06%-0.21%+43.81%+74.92% 357.68B
Weighted average by Cap. +0.37%+0.02%+37.58%+79.72%

Financials

2026 *2027 *
Net sales 124M 109M 100M 92.49M 174M 11.98B 178M 1.2B 472M 5.87B 467M 457M 20.2B 229M 200M 185M 170M 321M 22.06B 328M 2.21B 868M 10.8B 860M 841M 37.18B
Net income -9.08M -7.93M -7.32M -6.75M -12.72M -874M -13M -87.5M -34.42M -428M -34.09M -33.35M -1.47B 75.14M 65.67M 60.6M 55.85M 105M 7.24B 108M 724M 285M 3.54B 282M 276M 12.2B
Net Debt - -
Logo Precigen, Inc.
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Employees
160
Date Price Change Volume
17/07/26 $4.950 0.00% 2,967,831
16/07/26 $4.950 -3.32% 3,943,713
15/07/26 $5.120 0.00% 1,917,884
14/07/26 $5.120 -0.97% 2,904,684
13/07/26 $5.170 -2.82% 3,042,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.950USD
Average target price
12.45USD
Spread / Average Target
+151.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PGEN Stock